PPARG and pulmonary arterial hypertension: Finally, given the striking convergence of actions of multiple genes implicated in heritable PAH, there is a compelling possibility of synergistic therapeutic effects of a rational combination of pharmacologic PPARγ activation along with the unique application of shortmer technology to repress the miR-130/301 family.